In vivo evaluation of the efficacy of combined albedazole-IFN-α treatment for cystic echinococcosis in mice
| Autor: | Shengbin Zhang, Xiaodong Zhang, Lifu Su, Baoqin Liu, Hao Wang, Yongsheng Zhou |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_treatment Secondary infection 030231 tropical medicine Alpha interferon Pharmacology Albendazole Mice 03 medical and health sciences 0302 clinical medicine Echinococcosis In vivo medicine Animals Humans Echinococcus granulosus Mice Inbred BALB C Chemotherapy General Veterinary biology Interferon-alpha Interleukin General Medicine 030108 mycology & parasitology biology.organism_classification medicine.disease Treatment Outcome Infectious Diseases Insect Science Immunology Female Parasitology medicine.drug |
| Zdroj: | Parasitology Research. 116:735-742 |
| ISSN: | 1432-1955 0932-0113 |
| DOI: | 10.1007/s00436-016-5339-0 |
| Popis: | Cystic echinococcosis (CE) is a serious helminthic zoonosis caused by Echinococcus granulosus metacestode worldwide. The current chemotherapy of CE is mainly based on albendazole (ABZ). However, more than 20% CE cases failed to such chemotherapy. Thus, novel and more efficient treatment options are urgently needed. This study was to evaluate the in vivo efficacy of combined ABZ-interferon (IFN)-α treatment for CE in mice. After 5 months of secondary infection with protoscoleces, mice were randomly allocated into four groups: ABZ-treated group, IFN-α-treated group, ABZ+IFN-α group, and untreated control group. Drugs in diverse treated groups were respectively administered for 2 months. Mice were then euthanized and associated indications were investigated to evaluate the therapeutic efficacy. ABZ+IFN-α induced a significant reduction of the number, size, as well as weight of cysts, compared with that in the ABZ (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink